{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:51:00Z","timestamp":1793321460768,"version":"4.5.0"},"reference-count":159,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T00:00:00Z","timestamp":1710547200000},"content-version":"am","delay-in-days":289,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["ZIADK031116"],"award-info":[{"award-number":["ZIADK031116"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["ZIADK031117"],"award-info":[{"award-number":["ZIADK031117"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.neuropharm.2023.109503","type":"journal-article","created":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T12:20:01Z","timestamp":1678710001000},"page":"109503","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["New paradigms in purinergic receptor ligand discovery"],"prefix":"10.1016","volume":"230","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8104-1493","authenticated-orcid":false,"given":"Kenneth A.","family":"Jacobson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balaram","family":"Pradhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asmita","family":"Pramanik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.neuropharm.2023.109503_bib1","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/0163-7258(94)00048-4","article-title":"Purinoceptors: are there families of P2X and P2Y purinoceptors?","volume":"64","author":"Abbracchio","year":"1994","journal-title":"Pharmacol. Therapeut."},{"key":"10.1016\/j.neuropharm.2023.109503_bib2","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s11302-015-9460-9","article-title":"Selectivity is species-dependent: characterization of standard agonists and antagonists at human, rat, and mouse adenosine receptors","volume":"11","author":"Alnouri","year":"2015","journal-title":"Purinergic Signal."},{"key":"10.1016\/j.neuropharm.2023.109503_bib3","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1021\/acs.jmedchem.0c01856","article-title":"Crystal structure and subsequent ligand design of a nonriboside partial agonist bound to the adenosine A2A receptor","volume":"64","author":"Amelia","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2023.109503_bib4","first-page":"1","article-title":"Stimulation of platelet P2Y1 receptors by different endogenous nucleotides leads to functional selectivity via biased signalling","volume":"2023","author":"Arkless","year":"2023","journal-title":"Br. J. Pharmacol."},{"issue":"11","key":"10.1016\/j.neuropharm.2023.109503_bib5","doi-asserted-by":"crossref","DOI":"10.4155\/fmc.15.69","article-title":"Pyrazin-2(1H)-ones as a novel class of selective A3 adenosine receptor antagonists","volume":"7","author":"Azuaje","year":"2015","journal-title":"Future Med. Chem."},{"issue":"1","key":"10.1016\/j.neuropharm.2023.109503_bib6","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1124\/mol.116.103283","article-title":"Structure-activity analysis of biased agonism at the human adenosine A3 receptor","volume":"90","author":"Baltos","year":"2016","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109503_bib7","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.bcp.2017.03.014","article-title":"Capadenoson, a clinically trialed partial adenosine A1 receptor agonist, can stimulate adenosine A2B receptor biased agonism","volume":"135","author":"Baltos","year":"2017","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109503_bib8","first-page":"91","article-title":"Chapter 5. A2A adenosine receptor: structures, modeling and medicinal chemistry","volume":"34","author":"Baraldi","year":"2018"},{"key":"10.1016\/j.neuropharm.2023.109503_bib9","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/0006-2952(92)90257-J","article-title":"Penetration of adenosine antagonists into mouse brain as determined by ex vivo binding","volume":"43","author":"Baumgold","year":"1992","journal-title":"Biochem. Pharmacol."},{"issue":"6","key":"10.1016\/j.neuropharm.2023.109503_bib10","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/j.drudis.2018.05.005","article-title":"Is the adenosine A2B \u2018biased\u2019receptor a valuable target for the treatment of pulmonary arterial hypertension?","volume":"23","author":"Bessa-Gon\u00e7alves","year":"2018","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.neuropharm.2023.109503_bib11","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ejmech.2018.02.081","article-title":"The aminopyridine-3, 5-dicarbonitrile core for the design of new non-nucleoside-like agonists of the human adenosine A2B receptor","volume":"150","author":"Betti","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2023.109503_bib158","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106460","article-title":"Synthesis and structure-activity relationships of ticlopidine derivatives and analogs as inhibitors of ectonucleotidase CD39","author":"Bi","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.neuropharm.2023.109503_bib12","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1124\/pr.112.006361","article-title":"Adenosine kinase: exploitation for therapeutic gain","volume":"65","author":"Boison","year":"2013","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2023.109503_bib13","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S0031-6997(25)06930-3","article-title":"Purinergic nerves","volume":"24","author":"Burnstock","year":"1972","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2023.109503_bib14","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/ddr.430310308","article-title":"Structure activity relationships for derivatives of adenosine-5\u2032-triphosphate as agonists at P2 purinoceptors: heterogeneity within P2X- and P2Y-subtypes","volume":"31","author":"Burnstock","year":"1994","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.neuropharm.2023.109503_bib15","doi-asserted-by":"crossref","first-page":"661","DOI":"10.3389\/fphar.2017.00661","article-title":"Purinergic signalling: therapeutic developments","volume":"8","author":"Burnstock","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109503_bib16","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/s41421-022-00503-1","article-title":"Structures of adenosine receptor A2BR bound to endogenous and synthetic agonists","volume":"8","author":"Cai","year":"2022","journal-title":"Cell Discov"},{"key":"10.1016\/j.neuropharm.2023.109503_bib17","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.neuropharm.2016.11.026","article-title":"Hypothermia in mouse is caused by adenosine A1 and A3 receptor agonists and AMP via three distinct mechanisms","volume":"114","author":"Carlin","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2023.109503_bib18","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.neuropharm.2018.02.035","article-title":"Activation of adenosine A2A or A2B receptors causes hypothermia in mice","volume":"139","author":"Carlin","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2023.109503_bib19","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1124\/mol.109.058578","article-title":"Quantification of Gi-mediated inhibition of adenylyl cyclase activity reveals that UDP is a potent agonist of the human P2Y14 receptor","volume":"76","author":"Carter","year":"2009","journal-title":"Mol. Pharmacol."},{"issue":"4","key":"10.1016\/j.neuropharm.2023.109503_bib20","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nrd3955","article-title":"Adenosine receptors as drug targets\u2014what are the challenges?","volume":"12","author":"Chen","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2023.109503_bib21","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11302-020-09694-2","article-title":"The belated US FDA approval of the adenosine A2A receptor antagonist istradefylline for treatment of Parkinson's disease","volume":"16","author":"Chen","year":"2020","journal-title":"Purinergic Signal."},{"issue":"51","key":"10.1016\/j.neuropharm.2023.109503_bib22","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.add3709","article-title":"Cryo-EM structure of the human adenosine A2B receptor\u2013Gs signaling complex","volume":"8","author":"Chen","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.neuropharm.2023.109503_bib23","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2147\/JAA.S151849","article-title":"A purinergic P2Y6 receptor agonist prodrug modulates airway inflammation, remodeling, and hyperreactivity in a mouse model of asthma","volume":"11","author":"Chetty","year":"2018","journal-title":"J. Asthma Allergy"},{"key":"10.1016\/j.neuropharm.2023.109503_bib24","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1021\/acs.jcim.7b00528","article-title":"Demystifying P2Y1 receptor ligand recognition through docking and molecular dynamics analyses","volume":"57","author":"Ciancetta","year":"2017","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.neuropharm.2023.109503_bib25","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2147\/DDDT.S195294","article-title":"Targeting the A3 adenosine receptor to treat cytokine release syndrome in cancer immunotherapy","volume":"13","author":"Cohen","year":"2019","journal-title":"Drug Des. Dev. Ther."},{"issue":"5","key":"10.1016\/j.neuropharm.2023.109503_bib26","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1021\/acs.jmedchem.9b01856","article-title":"Subtype-selective fluorescent ligands as pharmacological research tools for the human adenosine A2A receptor","volume":"63","author":"Comeo","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2023.109503_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114347","article-title":"P2Y4, P2Y6 and P2Y11 receptors: from the early days of cloning to their function","volume":"187","author":"Communi","year":"2021","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2023.109503_bib28","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.cell.2020.03.003","article-title":"Impact of GPCR structures on drug discovery","volume":"181","author":"Congreve","year":"2020","journal-title":"Cell"},{"issue":"22","key":"10.1016\/j.neuropharm.2023.109503_bib29","doi-asserted-by":"crossref","first-page":"9981","DOI":"10.1021\/acs.jmedchem.5b01972","article-title":"Drug-like antagonists of P2Y receptors\u2014from lead identification to drug development","volume":"59","author":"Conroy","year":"2016","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.neuropharm.2023.109503_bib30","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/sj.bjp.0705925","article-title":"Coupling of the human A1 adenosine receptor to different heterotrimeric G proteins: evidence for agonist\u2010specific G protein activation","volume":"143","author":"Cordeaux","year":"2004","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109503_bib31","doi-asserted-by":"crossref","first-page":"8887","DOI":"10.3390\/ijms23168887","article-title":"Ex vivo feedback control of neurotransmission using a photocaged adenosine A1 receptor agonist","volume":"23","author":"Craey","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2023.109503_bib32","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0165-1838(00)00151-X","article-title":"Platelet P2 receptors: from curiosity to clinical targets","volume":"81","author":"Cusack","year":"2000","journal-title":"J. Auton. Nerv. Syst."},{"key":"10.1016\/j.neuropharm.2023.109503_bib33","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1021\/acsmedchemlett.8b00524","article-title":"Investigation on 2',3'-O-substituted ATP derivatives and analogs as novel P2X3 receptor antagonists","volume":"10","author":"Dal Ben","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.neuropharm.2023.109503_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2019.113718","article-title":"A2A and A2B adenosine receptors: the extracellular loop 2 determines high (A2A) or low affinity (A2B) for adenosine","volume":"172","author":"De Filippo","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109503_bib35","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/s41586-021-03897-2","article-title":"Positive allosteric mechanisms of adenosine A1 receptor-mediated analgesia","volume":"597","author":"Draper-Joyce","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2023.109503_bib36","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1113\/jphysiol.1929.sp002608","article-title":"The physiological activity of adenine compounds with special reference to their action upon the mammalian heart","volume":"68","author":"Drury","year":"1929","journal-title":"J. Physiol."},{"key":"10.1016\/j.neuropharm.2023.109503_bib37","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41581-020-0304-7","article-title":"Conversion of extracellular ATP into adenosine: a master switch in renal health and disease","volume":"16","author":"Dwyer","year":"2020","journal-title":"Nat. Rev. Nephrol."},{"issue":"26","key":"10.1016\/j.neuropharm.2023.109503_bib38","doi-asserted-by":"crossref","first-page":"8228","DOI":"10.1021\/jacs.8b03805","article-title":"Extrinsic tryptophans as NMR probes of allosteric coupling in membrane proteins: application to the A2A adenosine receptor","volume":"140","author":"Eddy","year":"2018","journal-title":"J. Am. Chem. Soc."},{"issue":"2","key":"10.1016\/j.neuropharm.2023.109503_bib39","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.bcp.2009.08.010","article-title":"Adenosine A3 receptor-mediated cardioprotection against doxorubicin-induced mitochondrial damage","volume":"79","author":"Emanuelov","year":"2010","journal-title":"Biochem. Pharmacol."},{"issue":"22","key":"10.1016\/j.neuropharm.2023.109503_bib40","doi-asserted-by":"crossref","first-page":"15238","DOI":"10.1021\/acs.jmedchem.2c01170","article-title":"Structure activity studies of 1H-imidazo[4,5-c]quinolin-4-amine derivatives as A3 adenosine receptor positive allosteric modulators","volume":"65","author":"Fallot","year":"2022","journal-title":"J. Med. Chem."},{"issue":"15","key":"10.1016\/j.neuropharm.2023.109503_bib41","doi-asserted-by":"crossref","first-page":"4676","DOI":"10.3390\/molecules27154676","article-title":"Cancer-associated mutations of the adenosine A2A receptor have diverse influences on ligand binding and receptor functions","volume":"27","author":"Feng","year":"2022","journal-title":"Molecules"},{"issue":"8","key":"10.1016\/j.neuropharm.2023.109503_bib42","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1021\/acsptsci.2c00076","article-title":"Characterization of dual-acting A3 adenosine receptor allosteric modulators that preferentially enhance adenosine-induced G\u03b1i3 and G\u03b1oA isoprotein activation","volume":"5","author":"Fisher","year":"2022","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.neuropharm.2023.109503_bib43","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.3390\/molecules27123680","article-title":"Drugs targeting the A3 adenosine receptor: human clinical study data","volume":"27","author":"Fishman","year":"2022","journal-title":"Molecules"},{"issue":"146","key":"10.1016\/j.neuropharm.2023.109503_bib44","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003717","article-title":"Selective activation of adenosine A2A receptors on immune cells by a CD73-dependent prodrug suppresses joint inflammation in experimental rheumatoid arthritis","volume":"4","author":"Fl\u00f6gel","year":"2012","journal-title":"Sci. Transl. Med."},{"issue":"5","key":"10.1016\/j.neuropharm.2023.109503_bib45","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1021\/jm00400a022","article-title":"Structure-activity profile of a series of novel triazoloquinazoline adenosine antagonists","volume":"31","author":"Francis","year":"1988","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2023.109503_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.628601","article-title":"The old and new visions of biased agonism through the prism of adenosine receptor signaling and receptor\/receptor and receptor\/protein interactions","volume":"11","author":"Franco","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109503_bib47","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1007\/s00018-021-03761-6","article-title":"Structure and function of adenosine receptor heteromers","volume":"78","author":"Franco","year":"2021","journal-title":"Cell. Mol. Life Sci."},{"issue":"3","key":"10.1016\/j.neuropharm.2023.109503_bib48","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.bcp.2014.05.008","article-title":"Probing biased\/partial agonism at the G protein-coupled A2B adenosine receptor","volume":"90","author":"Gao","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109503_bib49","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1124\/mol.117.109660","article-title":"Distinct signaling patterns of allosteric antagonism at the P2Y1 receptor","volume":"92","author":"Gao","year":"2017","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109503_bib50","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.3390\/cells9051200","article-title":"Allosteric antagonism of the A2A adenosine receptor by a series of bitopic ligands","volume":"9","author":"Gao","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.neuropharm.2023.109503_bib51","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s11302-021-09823-5","article-title":"Pharmacological characterization of DPTN and other selective A3 adenosine receptor antagonists","volume":"17","author":"Gao","year":"2021","journal-title":"Purinergic Signal."},{"key":"10.1016\/j.neuropharm.2023.109503_bib52","article-title":"Species dependence of A3 adenosine receptor pharmacology and function","author":"Gao","year":"2022","journal-title":"Purinergic Signal."},{"key":"10.1016\/j.neuropharm.2023.109503_bib53","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00018-018-2960-3","article-title":"Deciphering biased inverse agonism of cangrelor and ticagrelor at P2Y12 receptor","volume":"76","author":"Garcia","year":"2019","journal-title":"Cell. Mol. Life Sci."},{"issue":"9","key":"10.1016\/j.neuropharm.2023.109503_bib54","article-title":"Antagonists of the human adenosine A2A receptor. Part 1: discovery and synthesis of thieno[3,2-d]pyrimidine-4-methanone derivatives","volume":"18","author":"Gillespie","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"1","key":"10.1016\/j.neuropharm.2023.109503_bib55","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1021\/jm800961g","article-title":"Antagonists of the human A2A adenosine receptor. 4. Design, synthesis, and preclinical evaluation of 7-aryltriazolo[4,5-d]pyrimidines","volume":"52","author":"Gillespie","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2023.109503_bib56","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1111\/j.1476-5381.2012.01897.x","article-title":"Functional efficacy of adenosine A2A receptor agonists is positively correlated to their receptor residence time","volume":"166","author":"Guo","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109503_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114689","article-title":"G protein-coupled purinergic P2Y receptor oligomerization: pharmacological changes and dynamic regulation","volume":"192","author":"Guo","year":"2021","journal-title":"Biochem. Pharmacol."},{"issue":"18","key":"10.1016\/j.neuropharm.2023.109503_bib58","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1021\/acschemneuro.1c00397","article-title":"Discovery of highly potent adenosine A1 receptors agonists: targeting positron emission tomography probes","volume":"12","author":"Guo","year":"2021","journal-title":"ACS Chem. Neurosci."},{"issue":"21","key":"10.1016\/j.neuropharm.2023.109503_bib59","doi-asserted-by":"crossref","first-page":"9824","DOI":"10.1021\/acs.jmedchem.9b01220","article-title":"The blood\u2013brain barrier (BBB) score","volume":"62","author":"Gupta","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2023.109503_bib60","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.csbj.2019.08.002","article-title":"Nucleotide sugar transporter SLC35 family structure and function","volume":"17","author":"Hadley","year":"2019","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"10","key":"10.1016\/j.neuropharm.2023.109503_bib61","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1074\/jbc.M117.810168","article-title":"Vesicular nucleotide transporter mediates ATP release and migration in neutrophils","volume":"293","author":"Harada","year":"2018","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.neuropharm.2023.109503_bib62","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1001\/jamaneurol.2015.2268","article-title":"Preladenant as an adjunctive therapy with levodopa in Parkinson disease: two randomized clinical trials and lessons learned","volume":"72","author":"Hauser","year":"2015","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neuropharm.2023.109503_bib63","first-page":"124","article-title":"Uridine nucleoside derivatives, compositions and methods of use","volume":"11","author":"Haydon","year":"2021","journal-title":"US Patent"},{"issue":"22","key":"10.1016\/j.neuropharm.2023.109503_bib64","doi-asserted-by":"crossref","first-page":"9576","DOI":"10.1021\/jm300845v","article-title":"N-substituted phenoxazine and acridone derivatives: structure-activity relationships of potent P2X4 receptor antagonists","volume":"55","author":"Hernandez-Olmos","year":"2012","journal-title":"J. Med. Chem."},{"issue":"6817","key":"10.1016\/j.neuropharm.2023.109503_bib65","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/35051599","article-title":"Identification of the platelet ADP receptor targeted by antithrombotic drugs","volume":"409","author":"Hollopeter","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2023.109503_bib66","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1021\/jm201229j","article-title":"Structure-activity relationships of truncated C2- or C8-substituted adenosine derivatives as dual acting A2A and A3 adenosine receptor ligands","volume":"55","author":"Hou","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2023.109503_bib67","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/s41392-021-00553-z","article-title":"From purines to purinergic signalling: molecular functions and human diseases","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.neuropharm.2023.109503_bib68","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1124\/pharmrev.121.000445","article-title":"International union of basic and clinical pharmacology. CXII: adenosine receptors \u2013 a further update","volume":"74","author":"Ijzerman","year":"2022","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2023.109503_bib69","doi-asserted-by":"crossref","DOI":"10.1111\/bph.15299","article-title":"Update of P2X receptor properties and their pharmacology: IUPHAR Review: 30","volume":"178","author":"Illes","year":"2021","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109503_bib70","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.lfs.2017.05.017","article-title":"Identification of novel selective P2Y6 receptor antagonists by high-throughput screening assay","volume":"180","author":"Ito","year":"2017","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2023.109503_bib71","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1021\/jm00391a046","article-title":"Binary drugs: conjugates of purines and a peptide that bind to both adenosine and substance P receptors","volume":"30","author":"Jacobson","year":"1987","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2023.109503_bib72","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0028-3908(97)00104-4","article-title":"Pharmacological characterization of novel A3 adenosine receptor-selective antagonists","volume":"36","author":"Jacobson","year":"1997","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2023.109503_bib73","doi-asserted-by":"crossref","first-page":"30272","DOI":"10.1074\/jbc.M001520200","article-title":"A novel pharmacological approach to treating cardiac ischemia: binary conjugates of A1 and A3 adenosine receptor agonists","volume":"275","author":"Jacobson","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2023.109503_bib74","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.tips.2007.01.006","article-title":"Neoceptors: reengineering GPCRs to recognize tailored ligands","volume":"28","author":"Jacobson","year":"2007","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2023.109503_bib75","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1021\/bc9000596","article-title":"Functionalized congener approach to the design of ligands for G protein\u2013coupled receptors (GPCRs)","volume":"20","author":"Jacobson","year":"2009","journal-title":"Bioconjugate Chem."},{"issue":"4","key":"10.1016\/j.neuropharm.2023.109503_bib76","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.bcp.2015.08.085","article-title":"New paradigms in GPCR drug discovery","volume":"98","author":"Jacobson","year":"2015","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109503_bib77","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3389\/fncel.2019.00124","article-title":"Historical and current adenosine receptor agonists in preclinical and clinical development","volume":"13","author":"Jacobson","year":"2019","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109503_bib78","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1111\/bph.15005","article-title":"Update of P2Y receptor pharmacology: IUPHAR Review: 27","volume":"177","author":"Jacobson","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109503_bib79","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11302-020-09717-y","article-title":"Tribute to Prof. Geoffrey Burnstock: transition of purinergic signaling to drug discovery","volume":"17","author":"Jacobson","year":"2021","journal-title":"Purinergic Signal."},{"key":"10.1016\/j.neuropharm.2023.109503_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114311","article-title":"Medicinal chemistry of P2 and adenosine receptors: common scaffolds adapted for multiple targets","volume":"187","author":"Jacobson","year":"2021","journal-title":"Biochem. Pharmacol."},{"issue":"22","key":"10.1016\/j.neuropharm.2023.109503_bib81","doi-asserted-by":"crossref","first-page":"13444","DOI":"10.1021\/acs.jmedchem.0c01044","article-title":"Targeting metabolism of extracellular nucleotides via inhibition of ectonucleotidases CD73 and CD39","volume":"63","author":"Jeffrey","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2023.109503_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128981","article-title":"Synthesis and pharmacological characterization of multiply substituted 2H-chromene derivatives as P2Y6 receptor antagonists","volume":"75","author":"Jung","year":"2022","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"10","key":"10.1016\/j.neuropharm.2023.109503_bib83","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.18240\/ijo.2019.10.06","article-title":"Changes of tear film lipid layer thickness by 3% diquafosol ophthalmic solutions in patients with dry eye syndrome","volume":"12","author":"Kang","year":"2019","journal-title":"Int. J. Ophthalmol."},{"issue":"5","key":"10.1016\/j.neuropharm.2023.109503_bib84","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1008936","article-title":"Can molecular dynamics simulations improve the structural accuracy and virtual screening performance of GPCR models?","volume":"17","author":"Kapla","year":"2021","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.neuropharm.2023.109503_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2020.109844","article-title":"Biased signaling as allosteric probe dependence","volume":"79","author":"Kenakin","year":"2021","journal-title":"Cell. Signal."},{"key":"10.1016\/j.neuropharm.2023.109503_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114408","article-title":"The P2Y\/P2X divide: how it began","volume":"187","author":"Kennedy","year":"2021","journal-title":"Biochem. Pharmacol."},{"issue":"12","key":"10.1016\/j.neuropharm.2023.109503_bib87","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1007\/s00210-019-01695-2","article-title":"Agonists activate different A2B adenosine receptor signaling pathways in MBA-MD-231 breast cancer cells with distinct potencies","volume":"392","author":"Kouss\u00e9mou","year":"2019","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109503_bib88","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s13075-022-02961-0","article-title":"Novel Alendronate-CGS21680 conjugate reduces bone resorption and induces new bone formation in models of post-menopausal osteoporosis and inflammatory osteolysis mouse models","volume":"24","author":"Larra\u00f1aga-Vera","year":"2022","journal-title":"Arthritis Res. Ther."},{"issue":"17","key":"10.1016\/j.neuropharm.2023.109503_bib89","doi-asserted-by":"crossref","first-page":"12525","DOI":"10.1021\/acs.jmedchem.1c00239","article-title":"Subtle chemical changes cross the boundary between agonist and antagonist: new A3 adenosine receptor homology models and structural network analysis can predict this boundary","volume":"64","author":"Lee","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2023.109503_bib90","doi-asserted-by":"crossref","DOI":"10.1093\/procel\/pwac025","article-title":"Structural insights into signal transduction of the purinergic receptors P2Y1R and P2Y12R","author":"Li","year":"2022","journal-title":"Protein & Cell"},{"key":"10.1016\/j.neuropharm.2023.109503_bib91","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s11302-020-09732-z","article-title":"Nucleotide P2Y1 receptor agonists are in vitro and in vivo prodrugs of A1\/A3 adenosine receptor agonists: implications for roles of P2Y1 and A1\/A3 receptors in health and disease","volume":"16","author":"Liston","year":"2020","journal-title":"Purinergic Signal."},{"key":"10.1016\/j.neuropharm.2023.109503_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114367","article-title":"Use of knockout mice to explore CNS effects of adenosine","volume":"187","author":"Lopes","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109503_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105731","article-title":"Optical control of adenosine A3 receptor function in psoriasis","volume":"170","author":"L\u00f3pez-Cano","year":"2021","journal-title":"Pharmacol. Res."},{"issue":"8","key":"10.1016\/j.neuropharm.2023.109503_bib94","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1021\/jm401643m","article-title":"Agonists for the adenosine A1 receptor with tunable residence time. A case for nonribose 4-amino-6-aryl-5-cyano-2-thiopyrimidines","volume":"57","author":"Louvel","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2023.109503_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128837","article-title":"Strategies for targeting the P2Y12 receptor in the central nervous system","volume":"71","author":"Ma","year":"2022","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.neuropharm.2023.109503_bib96","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1586\/ecp.09.57","article-title":"Design and application of locally delivered agonists of the adenosine A2A receptor","volume":"3","author":"Mantell","year":"2010","journal-title":"Expet Rev. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109503_bib97","article-title":"Sub-millisecond conformational dynamics of the A2A adenosine receptor revealed by single-molecule FRET","author":"Maslov","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.neuropharm.2023.109503_bib98","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1039\/D0SC04938G","article-title":"Ligand design by targeting a binding site water","volume":"12","author":"Matricon","year":"2021","journal-title":"Chem. Sci."},{"key":"10.1016\/j.neuropharm.2023.109503_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2021.109954","article-title":"Biased agonism at adenosine receptors","volume":"82","author":"McNeill","year":"2021","journal-title":"Cell. Signal."},{"key":"10.1016\/j.neuropharm.2023.109503_bib100","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1124\/jpet.109.157750","volume":"332","author":"Meis","year":"2010","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"4","key":"10.1016\/j.neuropharm.2023.109503_bib101","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s11302-014-9418-3","article-title":"UTP is not a biased agonist at human P2Y11 receptors","volume":"10","author":"Morrow","year":"2014","journal-title":"Purinergic Signal."},{"key":"10.1016\/j.neuropharm.2023.109503_bib102","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.bbamem.2010.12.017","article-title":"Recent developments in adenosine receptor ligands and their potential as novel drugs","volume":"1808","author":"M\u00fcller","year":"2011","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"10.1016\/j.neuropharm.2023.109503_bib104","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111754","article-title":"Structure-activity relationship study of NPP1 inhibitors based on uracil-N1-(methoxy)ethyl-\u03b2-phosphate scaffold","volume":"184","author":"Nassir","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2023.109503_bib105","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1016\/j.csbj.2020.09.028","article-title":"Experimental and computational analysis of biased agonism on full-length and a C-terminally truncated adenosine A2A receptor","volume":"18","author":"Navarro Brugal","year":"2020","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"6","key":"10.1016\/j.neuropharm.2023.109503_bib106","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1021\/acs.jcim.1c01235","article-title":"Discovery of P2Y2 receptor antagonist scaffolds through virtual high-throughput screening","volume":"62","author":"Neumann","year":"2022","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.neuropharm.2023.109503_bib107","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1126\/scisignal.abj0644","article-title":"Redox-dependent internalization of the purinergic P2Y6 receptor limits colitis progression","volume":"15","author":"Nishiyama","year":"2022","journal-title":"Sci. Signal."},{"key":"10.1016\/j.neuropharm.2023.109503_bib160","doi-asserted-by":"crossref","DOI":"10.1124\/molpharm.122.000633","article-title":"In vitro pharmacological profile of KW-6356, a novel adenosine A2A receptor antagonist\/inverse agonist","author":"Ohno","year":"2023","journal-title":"Mol. Pharmacol."},{"issue":"4","key":"10.1016\/j.neuropharm.2023.109503_bib108","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/ddr.10197","article-title":"Robert Berne: His place in the history of purine research","volume":"58","author":"Olsson","year":"2003","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.neuropharm.2023.109503_bib159","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.866097","article-title":"Extracellular cAMP-adenosine pathway signaling: A potential therapeutic target in chronic inflammatory airway diseases","volume":"13","author":"Pacini","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.neuropharm.2023.109503_bib109","doi-asserted-by":"crossref","first-page":"5949","DOI":"10.1021\/jm4007966","article-title":"Rational design of sulfonated A3 adenosine receptor-selective nucleosides as pharmacological tools to study chronic neuropathic pain","volume":"56","author":"Paoletta","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2023.109503_bib110","first-page":"187","article-title":"Safety evaluation of FM101, an A3 adenosine receptor modulator, in rat, for developing as therapeutics of glaucoma and hepatitis","volume":"19","author":"Park","year":"2020","journal-title":"EXCLI journal"},{"key":"10.1016\/j.neuropharm.2023.109503_bib111","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1030895","article-title":"Update on the recent development of allosteric modulators for adenosine receptors and their therapeutic applications","volume":"13","author":"Pasquini","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109503_bib112","doi-asserted-by":"crossref","first-page":"606","DOI":"10.3389\/fphar.2018.00606","article-title":"Emerging roles of nucleoside transporters","volume":"9","author":"Pastor-Anglada","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109503_bib113","series-title":"Topics in Medicinal Chemistry","doi-asserted-by":"crossref","DOI":"10.1007\/7355_2022_154","article-title":"Bifunctional tools to study adenosine receptors","author":"Payne","year":"2022"},{"key":"10.1016\/j.neuropharm.2023.109503_bib114","doi-asserted-by":"crossref","DOI":"10.1177\/1753466619877960","article-title":"DT-0111: a novel drug-candidate for the treatment of COPD and chronic cough","volume":"13","author":"Pelleg","year":"2019","journal-title":"Ther. Adv. Respir. Dis."},{"issue":"1","key":"10.1016\/j.neuropharm.2023.109503_bib115","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1021\/acs.jmedchem.2c01768","article-title":"Exploring the effect of halogenation in a series of potent and selective A2B adenosine receptor antagonists","volume":"66","author":"Prieto-D\u00edaz","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2023.109503_bib116","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.920643","article-title":"Machine learning for discovery of new ADORA modulators","volume":"13","author":"Puhl","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2023.109503_bib117","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1021\/acs.jmedchem.1c01763","article-title":"Heterobivalent ligand for the adenosine A2A-dopamine D2 receptor heteromer","volume":"65","author":"Pulido","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2023.109503_bib118","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.65417","article-title":"Localization, proteomics, and metabolite profiling reveal a putative vesicular transporter for UDP-glucose","volume":"10","author":"Qian","year":"2021","journal-title":"Elife"},{"key":"10.1016\/j.neuropharm.2023.109503_bib119","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.628060","article-title":"Pharmacological insights into safety and efficacy determinants for the development of adenosine receptor biased agonists in the treatment of heart failure","volume":"12","author":"Rueda","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109503_bib120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113907","article-title":"Adenosine receptor antagonists: recent advances and therapeutic perspective","volume":"227","author":"Saini","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.neuropharm.2023.109503_bib121","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/gutjnl-2020-320937","article-title":"NTPDase8 protects mice from intestinal inflammation by limiting P2Y6 receptor activation: identification of a new pathway of inflammation for the potential treatment of IBD","volume":"71","author":"Salem","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.neuropharm.2023.109503_bib122","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1002\/cmdc.202000465","article-title":"Purinergic signaling: impact of GPCR structures on rational drug design","volume":"15","author":"Salmaso","year":"2020","journal-title":"ChemMedChem"},{"key":"10.1016\/j.neuropharm.2023.109503_bib123","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1021\/jm1008659","article-title":"Discovery of phosphoric acid mono-{2-[(E\/Z)-4-(3,3-dimethyl-butyrylamino)-3,5-difluoro-benzoylimino]-thiazol-3-ylmethyl} Ester (Lu AA47070): a phosphonooxymethylene prodrug of a potent and selective hA2A receptor antagonist","volume":"54","author":"Sams","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2023.109503_bib124","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ejphar.2017.08.011","article-title":"Attenuation of Sunitinib-induced cardiotoxicity through the A3 adenosine receptor activation","volume":"814","author":"Sandhu","year":"2017","journal-title":"Eur. J. Pharmacol."},{"issue":"9","key":"10.1016\/j.neuropharm.2023.109503_bib125","first-page":"3115","article-title":"Molecular modeling approaches of selective adenosine receptor type 2A agonists as potential anti-inflammatory drugs","volume":"39","author":"Santos","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"1","key":"10.1016\/j.neuropharm.2023.109503_bib126","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1006\/abbi.2001.2616","article-title":"A retrospective of recombinant P2Y receptor subtypes and their pharmacology","volume":"397","author":"Sak","year":"2002","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.neuropharm.2023.109503_bib127","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ejps.2004.09.010","article-title":"Brain penetration of synthetic adenosine A1 receptor agonists in situ: role of the rENT1 nucleoside transporter and binding to blood constituents","volume":"24","author":"Schaddelee","year":"2005","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.neuropharm.2023.109503_bib128","first-page":"783","article-title":"Clinical-pharmacological studies with a new orally active adenosine derivative","volume":"22","author":"Schaumann","year":"1972","journal-title":"Drug Res."},{"issue":"4","key":"10.1016\/j.neuropharm.2023.109503_bib129","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1021\/acs.jmedchem.8b00686","article-title":"Two decades under the influence of the rule of five and the changing properties of approved oral drugs","volume":"62","author":"Shultz","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2023.109503_bib130","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.2174\/138161212799436430","article-title":"Multi-parameter optimization: identifying high quality compounds with a balance of properties","volume":"18","author":"Segall","year":"2012","journal-title":"Curr. Pharmaceut. Des."},{"issue":"7","key":"10.1016\/j.neuropharm.2023.109503_bib131","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1021\/acsmedchemlett.2c00099","article-title":"Surface plasmon resonance screening to identify active and selective adenosine receptor binding fragments","volume":"13","author":"Shepherd","year":"2022","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.neuropharm.2023.109503_bib132","doi-asserted-by":"crossref","first-page":"11648","DOI":"10.1021\/acs.jmedchem.2c00462","article-title":"GPCR agonist-to-antagonist conversion: enabling the design of nucleoside functional switches for the A2A adenosine receptor","volume":"65","author":"Shiriaeva","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2023.109503_bib133","doi-asserted-by":"crossref","first-page":"5739","DOI":"10.3390\/ijms23105739","article-title":"The P2X4 receptor: cellular and molecular characteristics of a promising neuroinflammatory target","volume":"23","author":"Sophocleous","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"48","key":"10.1016\/j.neuropharm.2023.109503_bib134","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2102178118","article-title":"G protein signaling\u2013biased mu opioid receptor agonists that produce sustained G protein activation are noncompetitive agonists","volume":"118","author":"Stahl","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"9","key":"10.1016\/j.neuropharm.2023.109503_bib135","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.chembiol.2012.07.014","article-title":"Fragment screening at adenosine-A3 receptors in living cells using a fluorescence-based binding assay","volume":"19","author":"Stoddart","year":"2012","journal-title":"Chem. Biol."},{"key":"10.1016\/j.neuropharm.2023.109503_bib136","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s11302-020-09715-0","article-title":"Design and in vivo activity of A3 adenosine receptor agonist prodrugs","volume":"16","author":"Suresh","year":"2020","journal-title":"Purinergic Signal."},{"key":"10.1016\/j.neuropharm.2023.109503_bib137","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jconrel.2018.05.033","article-title":"Remote control of movement disorders using a photoactive adenosine A2A receptor antagonist","volume":"283","author":"Taura","year":"2018","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.neuropharm.2023.109503_bib138","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1021\/acsmedchemlett.9b00637","article-title":"Direct comparison of (N)-methanocarba and ribose-containing 2-arylalkynyladenosine derivatives as A3 receptor agonists","volume":"11","author":"Tosh","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.neuropharm.2023.109503_bib139","doi-asserted-by":"crossref","first-page":"4334","DOI":"10.1021\/acs.jmedchem.0c00235","article-title":"Truncated (N)-methanocarba nucleosides as partial agonists at mouse and human A3 adenosine receptors: affinity enhancement by N6-(2-phenylethyl) substitution","volume":"63","author":"Tosh","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2023.109503_bib140","first-page":"434","article-title":"P2X4 receptor antagonist","volume":"11","author":"Ushioda","year":"2022","journal-title":"US Patent"},{"key":"10.1016\/j.neuropharm.2023.109503_bib141","article-title":"The impact of inosine on hippocampal synaptic transmission and plasticity involves the release of adenosine through equilibrative nucleoside transporters rather than the direct activation of adenosine receptors","author":"Valada","year":"2022","journal-title":"Purinergic Signal."},{"key":"10.1016\/j.neuropharm.2023.109503_bib142","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/j.bmc.2012.02.012","article-title":"Synthesis and P2Y2 receptor agonist activity of nucleotide 5\u2032-phosphonate analogues","volume":"20","author":"Van Poecke","year":"2012","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.neuropharm.2023.109503_bib143","doi-asserted-by":"crossref","first-page":"4036","DOI":"10.1111\/bph.14337","article-title":"New paradigms in adenosine receptor pharmacology: allostery, oligomerization and biased agonism","volume":"175","author":"Vecchio","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109503_bib144","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s11302-011-9232-0","article-title":"Functional selectivity of adenosine receptor ligands","volume":"7","author":"Verzijl","year":"2011","journal-title":"Purinergic Signal."},{"key":"10.1016\/j.neuropharm.2023.109503_bib145","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.1038\/s41467-022-31652-2","article-title":"Selective activation of G\u03b1ob by an adenosine A1 receptor agonist elicits analgesia without cardiorespiratory depression","volume":"13","author":"Wall","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neuropharm.2023.109503_bib146","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0014-5793(93)81397-I","article-title":"Cloning and functional expression of a brain G-protein-coupled ATP receptor","volume":"324","author":"Webb","year":"1993","journal-title":"FEBS (Fed. Eur. Biochem. Soc.) Lett."},{"key":"10.1016\/j.neuropharm.2023.109503_bib147","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1021\/acs.jmedchem.1c01964","article-title":"Bridged piperidine analogues of a high affinity naphthalene-based P2Y14R antagonist","volume":"65","author":"Wen","year":"2022","journal-title":"J. Med. Chem."},{"issue":"24","key":"10.1016\/j.neuropharm.2023.109503_bib148","doi-asserted-by":"crossref","first-page":"11194","DOI":"10.1021\/acs.jmedchem.9b01304","article-title":"Discovery and characterization of the potent and selective P2X4 inhibitor N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]-2-phenylacetamide (BAY-1797) and structure-guided amelioration of its CYP3A4 induction profile","volume":"62","author":"Werner","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2023.109503_bib149","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1021\/acsptsci.2c00128","article-title":"Effects of purinergic receptor deletion or pharmacologic modulation on pulmonary inflammation in mice","volume":"5","author":"Whitehead","year":"2022","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.neuropharm.2023.109503_bib150","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.bcp.2017.12.026","article-title":"A binding kinetics study of human adenosine A3 receptor agonists","volume":"153","author":"Xia","year":"2018","journal-title":"Biochem. Pharmacol."},{"issue":"3","key":"10.1016\/j.neuropharm.2023.109503_bib151","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3000161","article-title":"Physiology and effects of nucleosides in mice lacking all four adenosine receptors","volume":"17","author":"Xiao","year":"2019","journal-title":"PLoS Biol."},{"key":"10.1016\/j.neuropharm.2023.109503_bib152","doi-asserted-by":"crossref","DOI":"10.1007\/s11302-023-09924-3","article-title":"In vivo phenotypic validation of adenosine receptor-dependent activity of non-adenosine drugs","author":"Xiao","year":"2023","journal-title":"Purinergic Signal."},{"issue":"3","key":"10.1016\/j.neuropharm.2023.109503_bib153","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1124\/pharmrev.121.000528","article-title":"ATP and adenosine metabolism in cancer: exploitation for therapeutic gain","volume":"74","author":"Yegutkin","year":"2022","journal-title":"Pharmacol. Rev."},{"issue":"11","key":"10.1016\/j.neuropharm.2023.109503_bib154","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1021\/jacsau.2c00415","article-title":"The time and place for Nature in drug discovery","volume":"2","author":"Young","year":"2022","journal-title":"JACS Au"},{"issue":"16","key":"10.1016\/j.neuropharm.2023.109503_bib155","doi-asserted-by":"crossref","first-page":"7432","DOI":"10.1073\/pnas.89.16.7432","article-title":"Molecular cloning and characterization of an adenosine receptor: the A3 adenosine receptor","volume":"89","author":"Zhou","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"3","key":"10.1016\/j.neuropharm.2023.109503_bib156","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3390\/biom12030418","article-title":"Adenosine-metabolizing enzymes, adenosine kinase and adenosine deaminase, in cancer","volume":"12","author":"Zhulai","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.neuropharm.2023.109503_bib157","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s11302-020-09755-6","article-title":"Ectonucleoside triphosphate diphosphohydrolases and ecto-5\u2032-nucleotidase in purinergic signaling: how the field developed and where we are now","volume":"17","author":"Zimmermann","year":"2021","journal-title":"Purinergic Signal."}],"updated-by":[{"DOI":"10.1016\/j.neuropharm.2023.109731","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T00:00:00Z","timestamp":1702598400000}}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839082300093X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839082300093X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:23:02Z","timestamp":1758439382000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002839082300093X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":159,"alternative-id":["S002839082300093X"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2023.109503","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New paradigms in purinergic receptor ligand discovery","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2023.109503","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"109503"}}